Carvedilol and Metoprolol Succinate

Mechanism

Pharmacological Class and Group

Antihypertensive, antiarrhythmic and antianginal drugs from the group of Beta-Adrenergic Receptor Blockers (Beta-blockers). Carvedilol is a third-generation nonselective agent with added peripheral vasodilation activity; Metoprolol succinate is a second-generation cardioselective β₁ blocker with controlled release kinetics.

Mechanism of Action

Chronic hyperactivation of the sympathetic nervous system, through the sustained release of norepinephrine and adrenaline, is a central element in the pathophysiology of hypertension, ischemic heart disease and heart failure. This induces reflex compensatory vasoconstriction, persistent sinus tachycardia, and progressive destructive cellular remodeling of the myocardium mediated by direct catecholamine toxicity.

Comparative Receptor Profile and Molecular Effects

1. Metoprolol Succinate (β₁ Cardioselectivity): It selectively and competitively blocks the β₁ adrenergic receptors located predominantly in the sarcolemma membrane of the cells of the sinus node, the atrioventricular node and atrial/ventricular myocytes. This prevents coupling to the G_s subunit and decreases activation of adenylate cyclase:

Metoprolol Receptor β₁ ↓ cAMP ↓ Phosphorylation of Ca^{2+ Channels}

This results in direct negative inotropic, chronotropic, dromotropic and bathmotropic effects. Additionally, it reduces sympathetically induced renin release in the renal juxtaglomerular apparatus.

2. Carvedilol (Multi-receptor and Antioxidant Action):

• β₁ and β₂ blockade: Competitively antagonizes both receptor subtypes, reducing the total adrenergic response.
• Selective blockade of α₁ Receptors: Antagonizes α₁ adrenergic receptors located in the smooth muscle of peripheral blood vessels. This eliminates basal sympathetic vasoconstrictor tone, netly reducing peripheral vascular resistance (PVR) and decreasing ventricular afterload without generating a reflex tachycardia response.
• Intrinsic Antioxidant Effect: It is capable of chelating exogenous oxygen free radicals and inhibiting lipid peroxidation in myocyte membranes, mitigating progressive myocardial apoptosis.

Pharmacokinetics

High Resolution Pharmacokinetics

• Carvedilol: Rapid oral absorption that is slightly delayed with food. It has a bioavailability of 25% to 35% due to first-pass hepatic clearance mediated by the isoenzymes CYP2D6 and CYP2C9. It has a wide volume of distribution and high protein binding (98%). Its terminal elimination half-life is 7 to 10 hours. It is excreted 60% through the bile/fecal route and less than 16% through the urine.
• Metoprolol Succinate (Controlled Release Formulation): Formulated as microencapsulated pellets that release the drug at a constant rate independent of gastrointestinal pH. Bioavailability of 50%. Hepatic metabolism mediated almost exclusively by the enzyme CYP2D6. Its elimination half-life is 3 to 7 hours, but the continuous plasma profiles of controlled release ensure a stable therapeutic effect longer than 24 hours. Renal excretion of 95% in the form of inactive metabolites.

Indicators and dose

Clinical Indications and Uses

• Heart Failure with Reduced Ejection Fraction (HFrEF): Priority indication to reverse the toxicity of catecholamines. Demonstrated long-term survival benefit (COPERNICUS trials for carvedilol and MERIT-HF for metoprolol succinate).
• Ischemic Heart Disease (Angina Pectoris / Post-AMI): Reduces myocardial oxygen demand by attenuating the double product (Heart Rate × Ejection Blood Pressure).
• Heart Rate Control in Atrial Fibrillation: Due to prolonged conduction delay in the AV node.
• Systemic Arterial Hypertension: Especially carvedilol due to its concomitant peripheral vasodilator effect.

Dosage and Clinical Adjustment

Carvedilol:

• Heart Failure: Starting dose of 3,125 mg every 12 hours orally. Double the dose every 2 weeks as clinically tolerated. Usual maintenance dose of 25 mg to 50 mg every 12 hours (maximum authorized dose of 50 mg every 12 hours for weight over 85 kg).
• Hepatic Adjustment: Formally contraindicated in cirrhosis or severe active liver dysfunction due to its high basal hepatic metabolic clearance rate.

Metoprolol Succinate (Extended Release):

• Heart Failure: Starting dose of 12.5 mg to 25 mg once daily. Progressively double the dose every 2 weeks until the target maintenance dose of 200 mg once daily is reached.
• Renal/Hepatic Adjustment: Does not require initial dose adjustment in renal failure; titrate with caution in moderate liver disease.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Bronchial asthma or COPD with severe active bronchospastic component (critical risk of lethal bronchospasm due to β₂ blockade, especially with carvedilol).
• Severe sinus bradycardia (baseline heart rate < 50 bpm).
• Second or third degree atrioventricular block without normal functional permanent pacemaker.
• Cardiogenic shock or acute decompensated heart failure requiring active intravenous inotropic support.
• Sinus node disease.

Relative Contraindications

• Unstable diabetes mellitus (beta-blockers mask the autonomic warning symptoms of acute hypoglycemia, such as tachycardia and tremors).
• Advanced peripheral arterial disease (severe Raynaud's phenomenon), due to peripheral vasoconstriction due to uncounteracted β₂ blockade (in this case carvedilol is preferred).

Adverse Effects and Toxicity

• Sinus bradycardia and profound arterial hypotension: May require a reduction in the dose escalation rate.
• Acute bronchospasm: Exclusive to the loss of selectivity or the use of non-selective blockers.
• Fatigue, asthenia and generalized lethargy: Due to reduction in basal cardiac output and direct effects on the central nervous system of compounds with moderate lipophilicity (such as metoprolol).
• Male sexual dysfunction: Due to attenuation of the arterial flow of the erectile tissue.

Critical Toxicity: Abrupt Withdrawal Rebound Phenomenon

Prolonged pharmacological blockade of adrenergic receptors induces a compensatory cellular process of up-regulation, characterized by a massive increase in the density and sensitivity of β₁ receptors in the sarcolemma:

Chronic BB use ↑ β_{1 receptor density} Abrupt cessation Extreme sympathetic hyperresponsiveness

If the drug is abruptly discontinued, the myocardium is exposed to physiological levels of catecholamines with a doubled receptor density, triggering severe arterial hypertension crises, uncontrolled ventricular tachycardia, de novo myocardial ischemia and sudden death. Therapeutic withdrawal of any beta-blocker should always be done progressively over a minimum of 10 to 14 days.

Relevant Drug Interactions

• Non-Dihydropyridine Calcium Antagonists (Verapamil, Diltiazem): Deep negative inotropic and dromotropic synergism. It can cause complete AV blocks that are difficult to resolve and refractory asystole.
• Potent CYP2D6 inhibitors (Fluoxetine, Paroxetine, Quinidine): They block the hepatic metabolism of metoprolol and carvedilol, doubling their serum concentrations and severely increasing the risk of bradycardia and hypotension.
• Amiodarone and Digoxin: Increase the risk of severe bradycardia due to synergistic mechanisms on the sinus and atrioventricular node.